Bay Area's Pionyr Immunotherapeutics Scores $62M to Push Anti-Tumor Tech Towards Clinic Post author:Sam Post published:December 12, 2017 Post category:BioPharma Pionyr was founded in 2015 by a UCSF professor and a Genentech alum. Source: BioSpace You Might Also Like Tax Reform: A War on Life Sciences Innovation December 11, 2017 FDA Panel Unanimously Endorses Novartis AG's CAR-T Leukemia Drug July 12, 2017 One-Time CAR-T Leader Juno Shows Off Promising New Clinical Data November 1, 2017
